Screening for Preeclampsia US Preventive Services Task Force Recommendation Statement

被引:173
作者
Bibbins-Domingo, Kirsten [1 ]
Grossman, David C. [2 ]
Curry, Susan J. [3 ]
Barry, Michael J. [4 ]
Davidson, Karina W. [5 ]
Doubeni, Chyke A. [6 ]
Epling, John W., Jr. [7 ]
Kemper, Alex R. [8 ]
Krist, Alex H. [9 ,10 ]
Kurth, Ann E. [11 ]
Landefeld, C. Seth [12 ]
Mangione, Carol M. [13 ]
Phillips, William R. [14 ]
Phipps, Maureen G. [15 ]
Silverstein, Michael [16 ]
Simon, Melissa A. [17 ]
Tseng, Chien-Wen [18 ,19 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
[3] Univ Iowa, Iowa City, IA USA
[4] Harvard Med Sch, Boston, MA USA
[5] Columbia Univ, New York, NY USA
[6] Univ Penn, Philadelphia, PA 19104 USA
[7] Virginia Tech Caril Sch Med, Roanoke, VA USA
[8] Duke Univ, Durham, NC USA
[9] Fairfax Family Practice Residency, Fairfax, VA USA
[10] Virginia Commonwealth Univ, Richmond, VA USA
[11] Yale Univ, New Haven, CT USA
[12] Univ Alabama Birmingham, Birmingham, AL USA
[13] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
[14] Univ Washington, Seattle, WA 98195 USA
[15] Brown Univ, Providence, RI 02912 USA
[16] Boston Univ, Boston, MA 02215 USA
[17] Northwestern Univ, Evanston, IL USA
[18] Univ Hawaii, Honolulu, HI 96822 USA
[19] Pacific Hlth Res & Educ Inst, Honolulu, HI USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2017年 / 317卷 / 16期
关键词
PREGNANCY-RELATED MORTALITY; BLOOD-PRESSURE-MEASUREMENT; MATERNAL MORTALITY; MORBIDITY;
D O I
10.1001/jama.2017.3439
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth. SUBPOPULATION CONSIDERATIONS Preeclampsia is more prevalent among African American women than among white women. Differences in prevalence may be, in part, due to African American women being disproportionally affected by risk factors for preeclampsia. African American women also have case fatality rates related to preeclampsia 3 times higher than rates among white women. Inequalities in access to adequate prenatal care may contribute to poor outcomes associated with preeclampsia in African American women. OBJECTIVE To update the 1996 US Preventive Services Task Force (USPSTF) recommendation on screening for preeclampsia. EVIDENCE REVIEW The USPSTF reviewed the evidence on the accuracy of screening and diagnostic tests for preeclampsia, the potential benefits and harms of screening for preeclampsia, the effectiveness of risk prediction tools, and the benefits and harms of treatment of screen-detected preeclampsia. FINDINGS Given the evidence that treatment can reduce maternal and perinatal morbidity and mortality, and the well-established accuracy of blood pressure measurements, the USPSTF found adequate evidence that screening for preeclampsia results in a substantial benefit for the mother and infant. In addition, there is adequate evidence to bound the harms of screening for and treatment of preeclampsia as no greater than small. Therefore, the USPSTF concludes with moderate certainty that there is a substantial net benefit of screening for preeclampsia in pregnant women. CONCLUSIONS AND RECOMMENDATION The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. (B recommendation)
引用
收藏
页码:1661 / 1667
页数:7
相关论文
共 31 条
[1]   Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis [J].
Ananth, Cande V. ;
Keyes, Katherine M. ;
Wapner, Ronald J. .
BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
[2]   Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth [J].
Ananth, Cande V. ;
Vintzileos, Anthony M. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 195 (06) :1557-1563
[3]  
[Anonymous], 2013, HYPERTENSION PREGNAN
[4]  
[Anonymous], 1996, GUID CLIN PREV SERV
[5]   Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008 [J].
Bateman, Brian T. ;
Shaw, Kate M. ;
Kuklina, Elena V. ;
Callaghan, William M. ;
Seely, Ellen W. ;
Hernandez-Diaz, Sonia .
PLOS ONE, 2012, 7 (04)
[6]   Maternal Mortality and Morbidity in the United States: Where Are We Now? [J].
Creanga, Andreea A. ;
Berg, Cynthia J. ;
Ko, Jean Y. ;
Farr, Sherry L. ;
Tong, Van T. ;
Bruce, F. Carol ;
Callaghan, William M. .
JOURNAL OF WOMENS HEALTH, 2014, 23 (01) :3-9
[7]   Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial [J].
Duley, L ;
Farrell, B ;
Spark, P ;
Roberts, B ;
Watkins, K ;
Bricker, L ;
Wang, L ;
Armstrong, N ;
Tivnin, M ;
Salih, N ;
Hurst, A ;
Smyth, R ;
Cooper, S ;
Wilson, A ;
Bowler, U ;
Notman, J .
LANCET, 2002, 359 (9321) :1877-1890
[8]   Magnesium sulphate and other anticonvulsants for women with pre-eclampsia [J].
Duley, Lelia ;
Guelmezoglu, A. Metin ;
Henderson-Smart, David J. ;
Chou, Doris .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (11)
[9]   Maternal Mortality From Preeclampsia/Eclampsia [J].
Ghulmiyyah, Labib ;
Sibai, Baha .
SEMINARS IN PERINATOLOGY, 2012, 36 (01) :56-59
[10]   Preeclampsia Screening Evidence Report and Systematic Review for the US Preventive Services Task Force [J].
Henderson, Jillian T. ;
Thompson, Jamie H. ;
Burda, Brittany U. ;
Cantor, Amy .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (16) :1668-1683